C16 Lactosylceramide-d3 (d18:1/16:0-d3)
(Synonyms: C16 Lactosyl(β) Ceramide-d3 (d18:1/16:0-d3), LacCer(d18:1/16:0-d3), Lactosylceramide-d3 (d18:1/16:0-d3), N-ω-CD3-Hexadecanoyl-lactosylceramide, N-Hexadecanoyl Lactosylceramide-d3) 目录号 : GC46982A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
C16 Lactosylceramide-d3 (d18:1/16:0-d3) is intended for use as an internal standard for the quantification of C16 lactosylceramide by GC- or LC-MS. C16 Lactosylceramide is an endogenous bioactive sphingolipid.1 It forms membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs), suggesting a role in cell signaling. Plasma levels of C16 lactosylceramide are elevated in insulin-resistant cattle.2 C16 Lactosylceramide is also upregulated in a mouse model of Niemann-Pick type C1 disease, a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder.3 [Matreya, LLC. Catalog No. 1534]
1.Iwabuchi, K., Nakayama, H., Oizumi, A., et al.Role of ceramide from glycosphingolipids and its metabolites in immunological and inflammatory responses in humansMediators Inflamm.2015120748(2015) 2.Rico, J.E., Bandaru, V.V., Dorskind, J.M., et al.Plasma ceramides are elevated in overweight Holstein dairy cows experiencing greater lipolysis and insulin resistance during the transition from late pregnancy to early lactationJ. Dairy Sci.98(11)7757-7770(2015) 3.Praggastis, M., Tortelli, B., Zhang, J., et al.A murine Niemann-Pick C1 I1061T knock-in model recapitulates the pathological features of the most prevalent human disease alleleJ. Neurosci.35(21)8091-8106(2015)
| Cas No. | N/A | SDF | |
| 别名 | C16 Lactosyl(β) Ceramide-d3 (d18:1/16:0-d3), LacCer(d18:1/16:0-d3), Lactosylceramide-d3 (d18:1/16:0-d3), N-ω-CD3-Hexadecanoyl-lactosylceramide, N-Hexadecanoyl Lactosylceramide-d3 | ||
| Canonical SMILES | O[C@H]1[C@H](O[C@]2([H])O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@@H](CO)O[C@@H](OC[C@H](NC(CCCCCCCCCCCCCCC([2H])([2H])[2H])=O)[C@H](O)/C=C/CCCCCCCCCCCCC)[C@@H]1O | ||
| 分子式 | C46H84D3NO13 | 分子量 | 865.2 |
| 溶解度 | Chloroform:Methanol:Water (5:1:0.1): soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1558 mL | 5.779 mL | 11.558 mL |
| 5 mM | 0.2312 mL | 1.1558 mL | 2.3116 mL |
| 10 mM | 0.1156 mL | 0.5779 mL | 1.1558 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。